KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Retained Earnings (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Retained Earnings for 18 consecutive years, with -$2.7 billion as the latest value for Q1 2026.

  • For Q1 2026, Retained Earnings fell 9308.69% year-over-year to -$2.7 billion; the TTM value through Mar 2026 reached -$2.7 billion, down 9308.69%, while the annual FY2025 figure was -$2.6 billion, 16.95% down from the prior year.
  • Retained Earnings hit -$2.7 billion in Q1 2026 for Ionis Pharmaceuticals, down from -$2.6 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$26.0 million in Q3 2025 and bottomed at -$2.7 billion in Q1 2026.
  • Average Retained Earnings over 5 years is -$1.0 billion, with a median of -$63.1 million recorded in 2022.
  • Year-over-year, Retained Earnings surged 98.79% in 2025 and then tumbled 9308.69% in 2026.
  • Ionis Pharmaceuticals' Retained Earnings stood at -$57.5 million in 2022, then soared by 43.21% to -$32.6 million in 2023, then crashed by 6791.74% to -$2.2 billion in 2024, then fell by 16.95% to -$2.6 billion in 2025, then dropped by 3.52% to -$2.7 billion in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$2.7 billion, -$2.6 billion, and -$26.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.